{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00018703", "CSN": null, "TRF": "ORD_1289649_01", "MRN": "48102847", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1022754", "clinicalId": "1024134", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1289649_01", "SampleName": "US1241270.01", "Version": "0", "Sample": {"FM_Id": "ORD_1289649_01", "SampleId": "US1241270.01", "BlockId": "nan", "TRFNumber": "ORD_1289649_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2022_01_29", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "Elevated Tumor Fraction Not Detected", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-98319", "MRN": "48102847", "FullName": "\u6797\u660e\u5fd7", "FirstName": "Ming_Chih", "LastName": "Lin", "SubmittedDiagnosis": "Gastric Cardia Adenocarcinoma (From clinical diagnosis)", "Gender": "Male", "DOB": "1964_11_26", "OrderingMD": "\u9673\u660e\u6643", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2022_01_25", "ReceivedDate": "2022-02-10 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Gastric Cancer"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "11", "clinicalTrialCount": "0", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "CALR", "isVUS": "true", "variantName": "P243L"}, {"geneName": "CD22", "isVUS": "true", "variantName": "V267I"}, {"geneName": "FGFR1", "isVUS": "true", "variantName": "R80C"}, {"geneName": "KMT2A (MLL)", "isVUS": "true", "variantName": "A53V"}, {"geneName": "LTK", "isVUS": "true", "variantName": "splice site 997+1G>A"}, {"geneName": "MLL2", "isVUS": "true", "variantName": "P2349L"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "01", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "01"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). For patients with gastric cancer, increased TMB is reported to be associated with prolonged OS (Cai et al., 2020; 32141230, Zhao et al., 2021; 33510848, Wei et al., 2021; 33613701). One study observed that the OS and disease_free survival (DFS) benefits of postoperative chemotherapy were more pronounced in patients with TMB_low gastric cancer (stage Ib/II) compared to those with TMB_high; however, patients with stage III gastric cancer benefitted regardless of TMB level (Wang et al., 2021; 33687617). In esophageal cancer, patients with TMB_high who had not received radiotherapy had significantly reduced OS (p=0.038) compared to those with TMB_low (Yuan et al., 2019; 32165590). On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511) and anti_PD_1 (Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074) therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). In HNSCC, a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "GNAS", "Include": "true", "Alterations": {"Alteration": {"Name": "R201H", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R201H"}}, "Interpretation": "GNAS encodes the alpha subunit of the stimulatory G protein (Gs_alpha) (Hayward et al., 1998; 9860993). Gs_alpha is a guanine_nucleotide binding protein (G protein) that is involved in hormonal regulation of adenylate cyclase (Hayward et al., 1998; 9860993). GNAS has been reported to be amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). GNAS alterations that have been shown to result in constitutive activation of adenylyl cyclase and an increase in cellular cAMP concentration (Masters et al., 1989; 2549064, Graziano and Gilman, 1989; 2549065, Jang and Juhnn, 2001; 11322485, Landis et al., 1989; 2549426, Tobar_Rubin et al., 2013; 23288949, Mariot et al., 2011; 20887824) are predicted to be activating. Mutations at R201 specifically are commonly associated with McCune_Albright syndrome, a disease that can co_occur with various cancers in patients with GNAS activating mutations (Weinstein et al., 1991; 1944469, Collins et al., 2003; 12970318, Nault et al., 2012; 21835143). The highest incidences of GNAS mutations have been reported in intraductal papillary mucinous neoplasms (40_66%)(Furukawa et al., 2011; 22355676, Wu et al., 2011; 21775669) and appendiceal mucinous neoplasms (50_72%)(Nishikawa et al., 2013; 23403822, Singhi et al., 2014; 24925222) as well as in tumors affecting the peritoneum (22%), pituitary gland (20%), bone (14%), pancreas (11%), and small intestine (11%)(COSMIC, 2022)(Tate et al., 2019; 30371878). Amplification of GNAS has been reported in ovarian epithelial carcinomas (12_30%)(Cancer Genome Atlas Research Network., 2011; 21720365, Kan et al., 2010; 20668451, Tominaga et al., 2010; 20537689), colorectal adenocarcinoma (9%)(Cancer Genome Atlas Network., 2012; 22810696), stomach adenocarcinoma (7%)(Cancer Genome Atlas Research Network., 2014; 25079317), lung adenocarcinoma (6.5%)(Cancer Genome Atlas Research Network., 2014; 25079552), breast invasive carcinoma (6.5%)(Cancer Genome Atlas Network., 2012; 23000897), pancreatic adenocarcinoma (6%)(Bio_Witkiewicz et al., 2015; 25855536), and sarcomas (5.8%)(cBio_Barretina et al., 2010; 20601955). GNAS mutations are rare in hematological malignancies generally (COSMIC, 2022)(Tate et al., 2019; 30371878, cBio_Lohr et al., 2014; 24434212, Chapman et al., 2011; 21430775). Activating GNAS mutations have been identified in gastrointestinal polyps in 75% (3/4) of patients with McCune_Albright syndrome (Zacharin et al., 2011; 21357941). Amplification of GNAS has been associated with shorter progression_free survival in patients with ovarian cancer (Kan et al., 2010; 20668451, Tominaga et al., 2010; 20537689), while activating GNAS mutations have been correlated with tumor progression and poor prognosis in patients with gastric cancer (Alakus et al., 2009; 20027678). There are no therapies targeted to GNAS mutation in cancer. However, there is limited data indicating that a patient with appendiceal adenocarcinoma and a GNAS mutation (R201H) benefited from trametinib for 4 months (Ang et al., 2017; 28868010). Additionally, a patient with GNAS_mutated Erdheim_Chester disease exhibited a PR following treatment with single_agent trametinib (Saunders et al., 2019; 31740567).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI_H tumors reportedly make up 12_35% of sporadic gastric cancers (Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086, Cancer Genome Atlas Research Network, 2017; 28052061). In the context of diffuse_type gastric cancer, a higher frequency of MSI_H tumors has been reported in familial (28%, 7/25) versus sporadic (7%, 7/107) tumors; no difference in frequency of MSI_H tumors was observed for intestinal_type gastric cancer (Fang et al., 2013; 23555086). MSI_H tumors have been frequently associated with hypermethylation and loss of MLH1 expression in cancers of the upper gastrointestinal tract, including esophageal, gastroesophageal junction, and gastric adenocarcinomas (Fang et al., 2013; 23555086, Gu et al., 2009; 19621725, Sasaki et al., 2011; 22866067, Fleisher et al., 1999; 10070967, Vasavi et al., 2010; 21045259, Zhang et al., 2013; 24035280). MSI_H gastric cancers are associated with certain clinicopathological and molecular features, including intestinal type differentiation, antral location, advanced age, reduced lymph node metastasis, and better prognosis (Zhu et al., 2015; 26137290, Leung et al., 1999; 9892201, dos Santos et al., 1996; 8536886, Wu et al., 1998; 9537253, Seo et al., 2015; 26078567, Cancer Genome Atlas Research Network., 2014; 25079317). A retrospective meta_analysis of the prognostic role of MSI in gastric cancers reported an increased DFS and OS in patients with MSI_H versus MSS/MSI_Low (Pietrantonio et al., 2019; 31513484). Conversely, in the same study, MSI_H was a negative predictor of response and MSS/MSI_Low correlated with increased benefit for patients treated with chemotherapy plus surgery as opposed to surgery alone (Pietrantonio et al., 2019; 31513484). In gastroesophageal cancer, MSI_H status was associated with shorter PFS compared to MSS patients for patients treated with chemotherapy (mPFS 4.8 months vs 6.9 months, HR=0.4) (Janjigian et al., 2018; 29122777). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143) and PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "E358V", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E358V"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. TP53 is frequently mutated in cancers of the gastrointestinal tract, with alterations reported in 34\u201372% of esophageal, gastroesophageal junction, and gastric adenocarcinomas (Dulak et al., 2013; 23525077, Cancer Genome Atlas Research Network., 2014; 25079317, Sengpiel et al., 2009; 19160092, P\u00fchringer_Oppermann et al., 2006; 16538517). Overexpression of p53 protein, which may occur as a result of mutation, has been reported in approximately 36% of gastric cancers, with p53 expression reported to be more frequent in intestinal_type compared with diffuse_type gastric cancer (Lee et al., 2014; 23969480, Sezer et al., 2013; 23613399, Victorzon et al., 1996; 8664030, Gon\u00e7alves et al., 2011; 21116760). While some studies have reported no association between TP53 mutation status and prognosis in patients with esophageal carcinoma or gastroesophageal junction adenocarcinoma (Sengpiel et al., 2009; 19160092, P\u00fchringer_Oppermann et al., 2006; 16538517) others have associated TP53 mutation and elevated p53 expression with poor prognosis for patients with esophageal squamous cell carcinoma (Han et al., 2007; 17760650, Yamasaki et al., 2010; 19941080) or stomach cancer (Liu et al., 2012; 23285001, Wiksten et al., 2008; 18751407, Migliavacca et al., 2004; 15254976). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR_246 (Gourley et al., 2016; ASCO Abstract 5571, Lehmann et al., 2012; 22965953, Mohell et al., 2015; 26086967, Franssonet al., 2016; 27179933). In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, APR_246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Elevated Tumor Fraction Not Detected", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Elevated Tumor Fraction Not Detected"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": null, "References": {"Reference": [{"number": "0", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "1", "ReferenceId": "23525077", "FullCitation": "Dulak AM, et al. Nat. Genet. (2013) pmid: 23525077", "Include": "true"}, {"number": "2", "ReferenceId": "25079317", "FullCitation": "Nature (2014) pmid: 25079317", "Include": "true"}, {"number": "3", "ReferenceId": "19160092", "FullCitation": "Sengpiel C, et al. Cancer Invest. (2009) pmid: 19160092", "Include": "true"}, {"number": "4", "ReferenceId": "16538517", "FullCitation": "P\u00fchringer_Oppermann F, et al. J. Cancer Res. Clin. Oncol. (2006) pmid: 16538517", "Include": "true"}, {"number": "5", "ReferenceId": "23969480", "FullCitation": "Lee HE, et al. Pathobiology (2014) pmid: 23969480", "Include": "true"}, {"number": "6", "ReferenceId": "23613399", "FullCitation": "Sezer C, et al. J BUON () pmid: 23613399", "Include": "true"}, {"number": "7", "ReferenceId": "8664030", "FullCitation": "Victorzon M, et al. Eur. J. Cancer (1996) pmid: 8664030", "Include": "true"}, {"number": "8", "ReferenceId": "21116760", "FullCitation": "Gon\u00e7alves AR, et al. Pathol. Oncol. Res. (2011) pmid: 21116760", "Include": "true"}, {"number": "9", "ReferenceId": "17760650", "FullCitation": "Han U, et al. Dis. Esophagus (2007) pmid: 17760650", "Include": "true"}, {"number": "10", "ReferenceId": "19941080", "FullCitation": "Yamasaki M, et al. Ann. Surg. Oncol. (2010) pmid: 19941080", "Include": "true"}, {"number": "11", "ReferenceId": "23285001", "FullCitation": "Liu X, et al. PLoS ONE (2012) pmid: 23285001", "Include": "true"}, {"number": "12", "ReferenceId": "18751407", "FullCitation": "Wiksten JP, et al. Anticancer Res. () pmid: 18751407", "Include": "true"}, {"number": "13", "ReferenceId": "15254976", "FullCitation": "Migliavacca M, et al. J. Cell. Physiol. (2004) pmid: 15254976", "Include": "true"}, {"number": "14", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "15", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "16", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "17", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "18", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "19", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "20", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "21", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "22", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "23", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "24", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "25", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "26", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "27", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "28", "ReferenceId": "22965953", "FullCitation": "Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953", "Include": "true"}, {"number": "29", "ReferenceId": "26086967", "FullCitation": "Mohell N, et al. Cell Death Dis (2015) pmid: 26086967", "Include": "true"}, {"number": "30", "ReferenceId": "27179933", "FullCitation": "Fransson \u00c5, et al. J Ovarian Res (2016) pmid: 27179933", "Include": "true"}, {"number": "31", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "32", "ReferenceId": "30975914", "FullCitation": "Boudny M, et al. Haematologica (2019) pmid: 30975914", "Include": "true"}, {"number": "33", "ReferenceId": "28062704", "FullCitation": "Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704", "Include": "true"}, {"number": "34", "ReferenceId": "30127241", "FullCitation": "Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241", "Include": "true"}, {"number": "35", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "36", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "37", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "38", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "39", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "40", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "41", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "42", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "43", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "44", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "45", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "46", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "47", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "48", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "49", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "50", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "51", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "52", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "53", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "54", "ReferenceId": "15209621", "FullCitation": "Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621", "Include": "true"}, {"number": "55", "ReferenceId": "9537253", "FullCitation": "Wu MS, et al. Cancer Res. (1998) pmid: 9537253", "Include": "true"}, {"number": "56", "ReferenceId": "8536886", "FullCitation": "dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886", "Include": "true"}, {"number": "57", "ReferenceId": "23555086", "FullCitation": "Fang WL, et al. Biomed Res Int (2013) pmid: 23555086", "Include": "true"}, {"number": "58", "ReferenceId": "28052061", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2017) pmid: 28052061", "Include": "true"}, {"number": "59", "ReferenceId": "19621725", "FullCitation": "Gu M, et al. Hepatogastroenterology () pmid: 19621725", "Include": "true"}, {"number": "60", "ReferenceId": "22866067", "FullCitation": "Sasaki S, et al. Oncol Lett (2011) pmid: 22866067", "Include": "true"}, {"number": "61", "ReferenceId": "10070967", "FullCitation": "Fleisher AS, et al. Cancer Res. (1999) pmid: 10070967", "Include": "true"}, {"number": "62", "ReferenceId": "21045259", "FullCitation": "Vasavi M, et al. Cancer Biomark (2010) pmid: 21045259", "Include": "true"}, {"number": "63", "ReferenceId": "24035280", "FullCitation": "Zhang LH, et al. Pathol. Res. Pract. (2013) pmid: 24035280", "Include": "true"}, {"number": "64", "ReferenceId": "26137290", "FullCitation": "Zhu L, et al. Mol Clin Oncol (2015) pmid: 26137290", "Include": "true"}, {"number": "65", "ReferenceId": "9892201", "FullCitation": "Leung SY, et al. Cancer Res. (1999) pmid: 9892201", "Include": "true"}, {"number": "66", "ReferenceId": "26078567", "FullCitation": "Seo JY, et al. World J. Gastroenterol. (2015) pmid: 26078567", "Include": "true"}, {"number": "67", "ReferenceId": "31513484", "FullCitation": "Pietrantonio F, et al. J. Clin. Oncol. (2019) pmid: 31513484", "Include": "true"}, {"number": "68", "ReferenceId": "29122777", "FullCitation": "Janjigian YY, et al. Cancer Discov (2018) pmid: 29122777", "Include": "true"}, {"number": "69", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "70", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "71", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "72", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "73", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "74", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "75", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "76", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "77", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "78", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "79", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "80", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "81", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "82", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "83", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "84", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "85", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "86", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "87", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "88", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "89", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "90", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "91", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "92", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "93", "ReferenceId": "32141230", "FullCitation": "Cai L, et al. Cancer Commun (Lond) (2020) pmid: 32141230", "Include": "true"}, {"number": "94", "ReferenceId": "33510848", "FullCitation": "Zhao DY, et al. World J Gastrointest Oncol (2021) pmid: 33510848", "Include": "true"}, {"number": "95", "ReferenceId": "33613701", "FullCitation": "Wei XL, et al. Ther Adv Med Oncol (2021) pmid: 33613701", "Include": "true"}, {"number": "96", "ReferenceId": "33687617", "FullCitation": "Wang D, et al. Gastric Cancer (2021) pmid: 33687617", "Include": "true"}, {"number": "97", "ReferenceId": "32165590", "FullCitation": "Yuan C, et al. Aging (Albany NY) (2020) pmid: 32165590", "Include": "true"}, {"number": "98", "ReferenceId": "9860993", "FullCitation": "Hayward BE, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9860993", "Include": "true"}, {"number": "99", "ReferenceId": "24071852", "FullCitation": "Zack TI, et al. Nat. Genet. (2013) pmid: 24071852", "Include": "true"}, {"number": "100", "ReferenceId": "20164920", "FullCitation": "Beroukhim R, et al. Nature (2010) pmid: 20164920", "Include": "true"}, {"number": "101", "ReferenceId": "2549064", "FullCitation": "Masters SB, et al. J. Biol. Chem. (1989) pmid: 2549064", "Include": "true"}, {"number": "102", "ReferenceId": "2549065", "FullCitation": "Graziano MP, et al. J. Biol. Chem. (1989) pmid: 2549065", "Include": "true"}, {"number": "103", "ReferenceId": "11322485", "FullCitation": "Jang IS, et al. Exp. Mol. Med. (2001) pmid: 11322485", "Include": "true"}, {"number": "104", "ReferenceId": "2549426", "FullCitation": "Landis CA, et al. Nature (1989) pmid: 2549426", "Include": "true"}, {"number": "105", "ReferenceId": "23288949", "FullCitation": "Tobar_Rubin R, et al. J. Mol. Endocrinol. (2013) pmid: 23288949", "Include": "true"}, {"number": "106", "ReferenceId": "20887824", "FullCitation": "Mariot V, et al. Bone (2011) pmid: 20887824", "Include": "true"}, {"number": "107", "ReferenceId": "1944469", "FullCitation": "Weinstein LS, et al. N. Engl. J. Med. (1991) pmid: 1944469", "Include": "true"}, {"number": "108", "ReferenceId": "12970318", "FullCitation": "Collins MT, et al. J. Clin. Endocrinol. Metab. (2003) pmid: 12970318", "Include": "true"}, {"number": "109", "ReferenceId": "21835143", "FullCitation": "Nault JC, et al. J. Hepatol. (2012) pmid: 21835143", "Include": "true"}, {"number": "110", "ReferenceId": "22355676", "FullCitation": "Furukawa T, et al. Sci Rep (2011) pmid: 22355676", "Include": "true"}, {"number": "111", "ReferenceId": "21775669", "FullCitation": "Wu J, et al. Sci Transl Med (2011) pmid: 21775669", "Include": "true"}, {"number": "112", "ReferenceId": "23403822", "FullCitation": "Nishikawa G, et al. Br. J. Cancer (2013) pmid: 23403822", "Include": "true"}, {"number": "113", "ReferenceId": "24925222", "FullCitation": "Singhi AD, et al. Hum. Pathol. (2014) pmid: 24925222", "Include": "true"}, {"number": "114", "ReferenceId": "21720365", "FullCitation": "Nature (2011) pmid: 21720365", "Include": "true"}, {"number": "115", "ReferenceId": "20668451", "FullCitation": "Kan Z, et al. Nature (2010) pmid: 20668451", "Include": "true"}, {"number": "116", "ReferenceId": "20537689", "FullCitation": "Tominaga E, et al. Gynecol. Oncol. (2010) pmid: 20537689", "Include": "true"}, {"number": "117", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "118", "ReferenceId": "23000897", "FullCitation": "Nature (2012) pmid: 23000897", "Include": "true"}, {"number": "119", "ReferenceId": "25855536", "FullCitation": "Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536", "Include": "true"}, {"number": "120", "ReferenceId": "20601955", "FullCitation": "Barretina J, et al. Nat. Genet. (2010) pmid: 20601955", "Include": "true"}, {"number": "121", "ReferenceId": "24434212", "FullCitation": "Lohr JG, et al. Cancer Cell (2014) pmid: 24434212", "Include": "true"}, {"number": "122", "ReferenceId": "21430775", "FullCitation": "Chapman MA, et al. Nature (2011) pmid: 21430775", "Include": "true"}, {"number": "123", "ReferenceId": "21357941", "FullCitation": "Zacharin M, et al. J. Med. Genet. (2011) pmid: 21357941", "Include": "true"}, {"number": "124", "ReferenceId": "20027678", "FullCitation": "Alakus H, et al. World J. Gastroenterol. (2009) pmid: 20027678", "Include": "true"}, {"number": "125", "ReferenceId": "28868010", "FullCitation": "Ang C, et al. Case Rep Oncol () pmid: 28868010", "Include": "true"}, {"number": "126", "ReferenceId": "31740567", "FullCitation": "Saunders IM, et al. Oncologist (2019) pmid: 31740567", "Include": "true"}, {"number": "127", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "128", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "129", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "130", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "131", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "132", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "133", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "134", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "135", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "136", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "137", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "138", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "139", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "140", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "141", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "142", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_02_07 14:52:15", "OpName": "J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "0%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "STOMACH", "disease_ontology": "Stomach adenocarcinoma (NOS)", "flowcell_analysis": "2000019933", "gender": "male", "pathology_diagnosis": "Gastric cancer", "pipeline_version": "v3.10.0", "purity_assessment": "10.0", "specimen": "ORD_1289649_01*US1241270.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1289649_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1241270.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4897", "cds_effect": "7046C>T", "depth": "2334", "equivocal": "false", "functional_effect": "missense", "gene": "MLL2", "percent_reads": "48.97", "position": "chr12:49434507", "protein_effect": "P2349L", "status": "unknown", "strand": "_", "transcript": "NM_003482", "dna_evidence": {"sample": "SQ_US1241270.01_1"}}, {"allele_fraction": "0.4867", "cds_effect": "728C>T", "depth": "1311", "equivocal": "false", "functional_effect": "missense", "gene": "CALR", "percent_reads": "48.67", "position": "chr19:13051380", "protein_effect": "P243L", "status": "unknown", "strand": "+", "transcript": "NM_004343", "dna_evidence": {"sample": "SQ_US1241270.01_1"}}, {"allele_fraction": "0.0048", "cds_effect": "602G>A", "depth": "4350", "equivocal": "false", "functional_effect": "missense", "gene": "GNAS", "percent_reads": "0.48", "position": "chr20:57484421", "protein_effect": "R201H", "status": "known", "strand": "+", "transcript": "NM_000516", "dna_evidence": {"sample": "SQ_US1241270.01_1"}}, {"allele_fraction": "0.4941", "cds_effect": "799G>A", "depth": "1957", "equivocal": "false", "functional_effect": "missense", "gene": "CD22", "percent_reads": "49.41", "position": "chr19:35828738", "protein_effect": "V267I", "status": "unknown", "strand": "+", "transcript": "NM_001771", "dna_evidence": {"sample": "SQ_US1241270.01_1"}}, {"allele_fraction": "0.4565", "cds_effect": "997+1G>A", "depth": "276", "equivocal": "false", "functional_effect": "splice", "gene": "LTK", "percent_reads": "45.65", "position": "chr15:41803361", "protein_effect": "splice site 997+1G>A", "status": "unknown", "strand": "_", "transcript": "NM_002344", "dna_evidence": {"sample": "SQ_US1241270.01_1"}}, {"allele_fraction": "0.56", "cds_effect": "158C>T", "depth": "25", "equivocal": "false", "functional_effect": "missense", "gene": "MLL", "percent_reads": "56.0", "position": "chr11:118307385", "protein_effect": "A53V", "status": "unknown", "strand": "+", "transcript": "NM_005933", "dna_evidence": {"sample": "SQ_US1241270.01_1"}}, {"allele_fraction": "0.0031", "cds_effect": "238C>T", "depth": "6527", "equivocal": "false", "functional_effect": "missense", "gene": "FGFR1", "percent_reads": "0.31", "position": "chr8:38287320", "protein_effect": "R80C", "status": "unknown", "strand": "_", "transcript": "NM_023110", "dna_evidence": {"sample": "SQ_US1241270.01_1"}}, {"allele_fraction": "0.5141", "cds_effect": "1073A>T", "depth": "5692", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "51.41", "position": "chr17:7573954", "protein_effect": "E358V", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1241270.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "1.26", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HPV_16", "reads_per_million": "33", "status": "unknown", "dna_evidence": {"sample": "SQ_US1241270.01_1"}}, {"organism": "HHV_4", "reads_per_million": "51", "status": "unknown", "dna_evidence": {"sample": "SQ_US1241270.01_1"}}, {"organism": "HHV_8", "reads_per_million": "21", "status": "unknown", "dna_evidence": {"sample": "SQ_US1241270.01_1"}}]}}}}}